Agnès J. van de Wouw

Supplementary Table S1 from Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01)

Anne F. de Groot, Danielle Cohen, Joan B. Heijns, Caroline M.P.W. Mandigers et autres

Supplementary Table S1. Representativeness of study participants.

Data from Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01)

Anne F. de Groot, Danielle Cohen, Joan B. Heijns, Caroline M.P.W. Mandigers et autres

AbstractPurpose: In hormone receptor–positive, HER2-negative, early-stage breast cancer, cyclin-dependent kinase 4 and 6 inhibition combined with endocrine therapy could represent a less toxic alternative to neoadjuvant chemotherapy (CT). The NEOLBC trial studied whether neoadjuvant ribociclib plus letrozole (RL) results in a doubling …

Supplementary Appendix S1 from Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01)

Anne F. de Groot, Danielle Cohen, Joan B. Heijns, Caroline M.P.W. Mandigers et autres

Supplementary Appendix S1. Study protocol.

nl, pk, it (code pays fourni par la source)

Supplementary Table S2 from Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01)

Anne F. de Groot, Danielle Cohen, Joan B. Heijns, Caroline M.P.W. Mandigers et autres

Supplementary Table S2. Pathological outcome (Ki67% and MP) to either neoadjuvant RL or CT.

Supplementary Table S3 from Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01)

Anne F. de Groot, Danielle Cohen, Joan B. Heijns, Caroline M.P.W. Mandigers et autres

Supplementary Table S3. Pathological outcome (Ki67% and MP) to either neoadjuvant RL or CT.

Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01)

Anne F. de Groot, Danielle Cohen, Joan B. Heijns, Caroline M.P.W. Mandigers et autres

PURPOSE: In hormone receptor-positive, HER2-negative, early-stage breast cancer, cyclin-dependent kinase 4 and 6 inhibition combined with endocrine therapy could represent a less toxic alternative to neoadjuvant chemotherapy (CT). The NEOLBC trial studied whether neoadjuvant ribociclib plus letrozole (RL) results in a doubling …

nl, us (code pays fourni par la source)

Examining the feasibility of cognitive bias modification for patients with cancer and survivors in 3 independent pilot studies

Demi D. Tenschert, Joyce Wilbers, Patrick Eichelsheim, Valerie Delbressine et autres

Abstract Objective: Cancer comes with considerable psychological and emotional distress, which can persist long after initial treatment. Yet, few digital interventions targeting emotional distress are available for patients with cancer and survivors. Cognitive bias modification (CBM) is a digital intervention designed to …

nl (code pays fourni par la source)

Primaire tumor onbekend

Agnès J. van de Wouw, L. I. Kroeze, L. A. S. Scheffers

Primaire tumor onbekend

Agnès J. van de Wouw, L. I. Kroeze, L. A. S. Scheffers

Nutritional intervention during a teleprehabilitation pilot study in high-risk patients with colorectal cancer: adherence, motivators, and barriers

K. Beukers, Ruud F. W. Franssen, K. Beijaard, Agnès J. van de Wouw et autres

PURPOSE: The preoperative period provides a window of opportunity to improve modifiable risk factors for treatment complications such as malnutrition, the so-called prehabilitation. Identifying factors related to adherence to nutritional interventions is essential for optimizing prehabilitation programs. The aim of this study …

nl (code pays fourni par la source)

The risk of fragility fractures in men with prostate cancer treated with androgen deprivation therapy

Marsha van Oostwaard, Caroline E. Wyers, Johanna H. M. Driessen, Maud A. van Maren et autres

Androgen Deprivation Therapy (ADT) increases long-term fracture risk in prostate cancer. Our study showed a higher fracture risk within six months of ADT use, and current use was associated with a higher risk of fragility fractures. Attention is needed for the prevention …

nl (code pays fourni par la source)

Development of a Multidisciplinary Care Pathway for Fracture Prevention in Men with Prostate Cancer at Initiation of Androgen Deprivation Therapy

Marsha van Oostwaard, Joop P. van den Bergh, Agnès J. van de Wouw, Marc de Jong et autres

Fracture risk is increased in men with prostate cancer (PCa) receiving Androgen Deprivation Therapy (ADT). However, routine assessment of fracture risk is often not systematically applied. We aimed to establish a comprehensive care pathway for fracture prevention in men with PCa starting …

nl (code pays fourni par la source)